Quince Therapeutics, Inc. (QNCX)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
31.73 USD
+2.37
(8.072%)
⇧
(Oct. 9, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 3:55 a.m. EDT
This biotech stock is currently trapped in a severe structural decline, having lost over 92% of its value over the past six years despite a recent annual rebound. While the company recently presented positive Phase 2a data for its LAM-001 therapy and secured a merger deal, the balance sheet remains fundamentally broken with negative book value, massive losses, and no free cash flow. The market has correctly priced these risks, and the recent price surge appears to be a volatile, speculative reaction rather than a sustainable recovery given the lack of institutional support. With no dividend to provide income and a statistical forecast leaning slightly negative due to low confidence, the immediate outlook remains perilous for capital preservation. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.262315 |
| AutoARIMA | 0.267547 |
| AutoETS | 0.270319 |
| AutoTheta | 0.270477 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 0.64 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.532 |
| Excess Kurtosis | 0.05 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 32,271,408 |
| Forward P/E | -6.78 |
| Beta | 1.33 |
| Previous Name | Cortexyme, Inc. |
| Website | https://quincetx.com |
As of Oct. 10, 2026, 3:55 a.m. EDT: Options activity shows negligible volume and open interest across all strikes for both calls and puts. The lack of liquidity and positioning data suggests a complete absence of speculative interest or directional bets from market participants, rendering the options chain useless for gauging near-term sentiment.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.91067207 |
| Address1 | 611 Gateway Boulevard |
| Address2 | Suite 273 |
| All Time High | 24,396.0 |
| All Time Low | 15.1 |
| Ask | 34.15 |
| Ask Size | 7 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 49,870 |
| Average Daily Volume3 Month | 29,957 |
| Average Volume | 29,957 |
| Average Volume10Days | 49,870 |
| Beta | 1.332 |
| Bid | 20.67 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | -34.731 |
| City | South San Francisco |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 31.73 |
| Current Ratio | 14.519 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 37.0 |
| Day Low | 29.8396 |
| Display Name | Quince Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,786,710,600 |
| Earnings Timestamp End | 1,794,513,600 |
| Earnings Timestamp Start | 1,794,513,600 |
| Ebitda | -60,647,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.991 |
| Enterprise Value | 60,101,408 |
| Eps Current Year | -3.65333 |
| Eps Forward | -4.68333 |
| Eps Trailing Twelve Months | -214.01 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 30.7868 |
| Fifty Day Average Change | 0.94319916 |
| Fifty Day Average Change Percent | 0.030636478 |
| Fifty Two Week Change Percent | -91.06721 |
| Fifty Two Week High | 910.0 |
| Fifty Two Week High Change | -878.27 |
| Fifty Two Week High Change Percent | -0.9651319 |
| Fifty Two Week Low | 15.1 |
| Fifty Two Week Low Change | 16.63 |
| Fifty Two Week Low Change Percent | 1.1013244 |
| Fifty Two Week Range | 15.1 - 910.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,557,408,600,000 |
| Float Shares | 679,683 |
| Forward Eps | -4.68333 |
| Forward P E | -6.7750936 |
| Free Cashflow | -25,748,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 38 |
| Fullday Change | 2.369999 |
| Fullday Change Percent | 8.072204 |
| Fullday Price | 31.73 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02901 |
| Held Percent Institutions | 0.34495 |
| Implied Shares Outstanding | 1,017,063 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,782,777,600 |
| Last Split Factor | 1:20 |
| Long Business Summary | Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consist of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California. |
| Long Name | Quince Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 32,271,408 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_266230063 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-12 |
| Net Income To Common | -92,476,000 |
| New Symbol | IRLA |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 30,003,358 |
| Number Of Analyst Opinions | 8 |
| Open | 30.5 |
| Operating Cashflow | -46,923,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Phone | 415 910 5717 |
| Prev Name | Cortexyme, Inc. |
| Previous Close | 29.36 |
| Price Eps Current Year | -8.685226 |
| Price Hint | 2 |
| Price To Book | -0.91359305 |
| Profit Margins | 0.0 |
| Quick Ratio | 14.233 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.44444 |
| Region | US |
| Regular Market Change | 2.37 |
| Regular Market Change Percent | 8.0722 |
| Regular Market Day High | 37.0 |
| Regular Market Day Low | 29.8396 |
| Regular Market Day Range | 29.8396 - 37.0 |
| Regular Market Open | 30.5 |
| Regular Market Previous Close | 29.36 |
| Regular Market Price | 31.73 |
| Regular Market Time | 1,791,576,000 |
| Regular Market Volume | 138,744 |
| Return On Assets | -0.31508 |
| Return On Equity | -1.5384101 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 1,017,063 |
| Shares Percent Shares Out | 0.0589 |
| Shares Short | 59,944 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 56,989 |
| Short Name | Quince Therapeutics, Inc. |
| Short Percent Of Float | 0.0591 |
| Short Ratio | 2.92 |
| Source Interval | 15 |
| State | CA |
| Symbol | QNCX |
| Target High Price | 98.0 |
| Target Low Price | 65.0 |
| Target Mean Price | 75.0 |
| Target Median Price | 71.0 |
| Total Cash | 115,981,000 |
| Total Cash Per Share | 114.035 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -214.01 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 85.11895 |
| Two Hundred Day Average Change | -53.38895 |
| Two Hundred Day Average Change Percent | -0.62722754 |
| Type Disp | Equity |
| Volume | 138,744 |
| Website | https://quincetx.com |
| Zip | 94,080 |